Mycobacterium tuberculosis is one of the strongest reducers of nitrate among all mycobacteria. Reduction of nitrate to nitrite, mediated by nitrate reductase (NarGHJI) of M. tuberculosis, is induced during the dormant stage, and the enzyme has a respiratory function in the absence of oxygen. Nitrite reductase (NirBD) is also functional during aerobic growth when nitrite is the sole nitrogen source. However, the role of NirBD-mediated nitrite reduction during the dormancy is not yet characterized. Here, we analyzed nitrite reduction during aerobic growth as well as in a hypoxic dormancy model of M. tuberculosis in vitro. When nitrite was used as the sole nitrogen source in the medium, the organism grew and the reduction of nitrite was evident in both hypoxic and aerobic cultures of M. tuberculosis. Remarkably, the hypoxic culture of M. tuberculosis, compared to the aerobic culture, showed 32-and 4-fold-increased expression of nitrite reductase (NirBD) at the transcription and protein levels, respectively. More importantly, a nirBD mutant of M. tuberculosis was unable to reduce nitrite and compared to the wild-type (WT) strain had a >2-log reduction in viability after 240 h in the Wayne model of hypoxic dormancy. Dependence of M. tuberculosis on nitrite reductase (NirBD) was also seen in a human macrophage-based dormancy model where the nirBD mutant was impaired for survival compared to the WT strain. Overall, the increased expression and essentiality of nitrite reductase in the in vitro dormancy models suggested that NirBD-mediated nitrite reduction could be critical during the persistent stage of M. tuberculosis.T uberculosis (TB) accounts for 1.4 million deaths annually and remains a serious health problem worldwide (1). The ability of the causative agent, Mycobacterium tuberculosis, to adapt to changing hostile environments within the host and shift into a dormant state has been recognized as one of the major reasons for its successful survival in humans (2). The nonreplicating persistent form not only helps the pathogen escape from the host defense mechanisms but also gives the bacilli the advantage of remaining unaffected by standard antitubercular drugs (3). Longterm persistence of M. tuberculosis in the latent stage, during antitubercular therapy, could also assist the pathogen to develop not just tolerance but resistance to currently used drugs (4). Therapeutic intervention which can target and kill the dormant tubercle bacilli therefore would not only provide a novel approach to combat TB but could also pave the way for complete eradication of the disease. A comprehensive knowledge of the metabolic state and physiology of M. tuberculosis during latent disease is required in order to discover such therapeutic options. The limited methods available for studying dormancy in M. tuberculosis, though not well characterized, have shown some degree of resemblance to actual in vivo latency (5-7). Based on the observation that human lung granulomas, where the TB bacilli reside, are hypoxic, an in vitro model in wh...